Rifabutin

Psoriatic arthritis is an inflammatory arthropathy that is associated with psoriasis cutaneous lesions in 5 to 39% of the cases.1 Its etiopathogenesis is unknown. Recent studies suggest multifactorial heritage, implicating the action of various genes, with external triggering factors.2 Progresses in molecular genetics allowed the identification of the genetic loci of susceptibility to psoriasis, named Psors 1, 2, 3 and 4 in chromosomes 6p, 3 17q, and 1q3, respectively. Other loci of minor susceptibility have been found in chromosomes 16q and 20p. 3 Genetic research suggests that psoriasis is a polygenic disease that is highly influenced by external stimuli, 3 which could explain how genetic variability influences the widely varied therapeutical responses.4. Rifabutin may decrease the effectiveness of oral contraceptives!

Eleven normal rabbits mean weight, 2.6 kg ; were given 27.5 to 37.5 mg kg mean, 34.5 mg kg ; of a factor VIII antibody preparation in a volume of 2.0 to 2.5 mI kg. Six additional rabbits mean weight, 2.3 kg ; were injected with 1.75 mg kg of HN2 4 days before the administration of 33.0 to 36.0 mg kg of a factor VIII antibody preparation. Three rabbits with hereditary C6. Metzger-Price Fund Virginia and Juan Meyer Donna and Helmut Meyerbach Erika and Ernest Michael Daniel Mitnick Leo Model Foundation * Evelyn Morales Marion and Peter Mosheim Marilyn F. Mueller Elsa S. Nad and Abraham Nad Foundation * Roberta and Stephen Nash Susan and Michael Nash Nancy and Daniel Neff Ilse Nelson Fund Marguerite and Otto Nelson The Netter Foundation * The Alice and Fred Netter Foundation Hannah and Frank Neubauer Abbi and Paul Neuthaler Lore Newburg Vera and Edward Newman * Susan and Kenneth Newmark Betty and Ellis Nichols Karen Nichols Grace and Eric Nierenberg Tina Nordmann Frank M. Nothmann Patricia and Peter O'Connor Esther and Elmer Offenbacher Irma Oppenheimer Leah Mason Oppenheimer and John Oppenheimer Martin and Suzanne Oppenheimer Philanthropic Fund Wolfgang Oppenheimer Nadine Orloff * Joe Osnoss Fritzi and Herbert Owens Foundation Rhoda and Claus Pappenheimer Julie and David Passman Jennifer and Frederick Pazmino Eve and Stanley Peterfreund The William Petschek Family Stowe C. Phelps Marianne and Albert Phiebig The Picower Foundation Lawrence Pines Melvin Polisher Lina and Hans Popper Kurt & Gladys Preuss Fund The Michael F. Price Foundation. Blood samples for laboratory analysis were collected from the jugular vein with a plastic disposable syringe. The sample was immediately transferred to 3-mi glass tubes containing ethylenediaminetetraacetic acid EDTA ; for hematologic evaluation, and to 10-mi silicone-coated glass tubes containing no anticoagulant for serum biochemical studies. Total erythrocyte and leukocyte determinations were made with an electronic cell counter.a Slides for differential white cell counts were prepared and stained with Wright's stain: 100 cells were counted. Hematocrit values were obtained by the microhematocrit method. Hemoglobin was measured using a cyanomethemoglobin technique. The determined values were then used to calculate the red cell indices: mean corpuscular volume MCV ; , mean corpuscular hemoglobin MCH ; , and mean corpuscular hemoglobin concentration MCHC ; . Total serum protein was obtained with a refractometer. Serum levels of calcium, phosphorus, glucose, urea nitrogen, uric acid, cholesterol, total bilirubin, alkaline phosphatase, lactic dehydrogenase, and glutamic-oxaloacetic transaminase were measured with an autoanalyzer. Sodium and potassium levels were measured on a flame photometerH and chloride concentrations were determined with a chloridimeter and rifadin. LeGuin, Ursula K. see LeGuin, Ursula K. Pinkola, Clarissa see Pinkola, Clarissa Spretnek, Charlene see Spretnek, Charlene Walker, Alice see Walker, Alice Wicca see Wicca Dianic Feminist Spirituality Movement 647649 Con-spirando Women's Collective see Con-spirando Women's Collective Cyborgism see Cyborgism Feminine Principle of Creation 103 goddess spirituality 703 Starhawk see Starhawk feminist theology see Christianity 7d ; Feminist Theology Fenech, Louis E. contribution in this encyclopedia, see Sikhism Fengshui 292, 293, 296, Ferality 650652 Ferguson, Marilyn 804, 943, 1195, Ferlat, Anne contributions in this encyclopedia, see Kalash Culture Northwestern Pakistan Paganism Mari Mari El Republic, Russia ; fertility see Abortion; Breeding and Contraception; Fertility and Abortion; Fertility and Secularization; Judaism and the Population Crisis; Population and Consumption Contemporary Religious Responses; Population, Consumption, and Christian Ethics Fertility and Abortion 652656 Fertility and Secularization 657658 Fiala, Andrew contributions in this encyclopedia, see Creation Myths of the Ancient World; Ovid's Metamorphoses Ficino, Marsilio 63, 933, 1130, fiction see Apocalyptic Literature; Fantasy Fiction; Utopic Literature Field, David N. contribution in this encyclopedia, see Christianity 6c2 ; Calvin, John and the Reformed Tradition Field, Steven contribution in this encyclopedia, see Fengshui fig tree see organisms flora Figueroa, Robert Melchior contributions in this encyclopedia, see Chvez, Csar and the United Farm Workers; Environmental Justice and Environmental Racism Finch, Martha contribution in this encyclopedia, see Puritans Findhorn Foundation Community 658660 see also adjacent, Dorothy Maclean ; Fire 660663 and Promethius 89, 433 Anishnabeg Culture 9192 Aztecs 144145 ceremonial 158, 1065, 1243, divine celestial 63, 206, 714, domestic 57 Hinduism 763, 764, 766, internal 721, 1050, 1522 Jainism 893, 894 Yellowstone 1157 Fisher, Andy 1329 contributions in this encyclopedia, see Ecopsychology Fishers 120, 663665, 749, see also Fly Fishing; Sohappy, David and Salmon Spirituality ; fishing 41, 120, 213, see also Fishers; Fly Fishing ; Fisk, Pliny 665666 flora see organisms flora Floresta 666667 Flower song xochicuicatl 144, 146 adjacent to Aztec Religion Pre-Colombian ; Fly Fishing 667669 Foltz, Richard C. contributions in this encyclopedia, see Islam; Islam and Environmentalism in Iran; Islam, Animals and Vegetarianism; Izzi Dien; Nasr, Seyyed Hossein; Pure Brethren; Water in Islam; Water in Zoroastrianism foraging societies 112, 144, 313, see also Huaorani; Penan Hunter-Gatherers; Pygmies Mbuti Foragers ; and Bila Farmers of the Hari Forest; San Bushmen ; Religion ; Foreman, Dave see Radical Environmentalism forests cathedral 274, 278, 518 see also Cathedral Forests and the Felling of Sacred Groves ; deforestation 30, 38, 44, and Confucianism 410 and Neo-Humanism 48 Athonite peninsula 335. Individual financial information for these joint ventures is not listed for reasons of confidentiality. However, aggregate financial information for the joint ventures is as follows: December 31, 2003 Total sales . Operating income . Income before tax . Total current assets Total assets . Total equity . Long-term debt . 225 412 December 31, 2002 in g million ; 2, 416 422 December 31, 2001 2 and rifapentine. Important to wash out the bowel by drinking at least 4 large glasses of any clear liquid 8 ounces each ; . + Drink one sportdrink Gatorade, Power Aid, etc. The cartesian monads arising in this book are typically monads on presheaf categories. Very often they are familially representable in a sense defined shortly ; , and this section provides some of the theory of such monads. After some general preliminaries, we concentrate on the special case of presheaf categories [Bop , Set] where B is discrete, arriving eventually at an explicit description of finitary familially representable monads on such categories. This will be used in the next section to provide a link between symmetric and generalized multicategories. Let A be a category and B a small category. What should it mean for a functor T : A [Bop , Set] to be familially representable? If B is discrete then the answer is clear: for each b B the b-component Tb T - ; b ; : Set and rifaximin!

The effects of rifabutin and rifampicin treatment on CYP3A4 mRNA and protein expression are shown in Figure 3 A ; , B ; The expression of CYP3A4 mRNA in chimeric mice was induced 7.4- and 9.2-fold by treatment with rifabutin and rifampicin, respectively. The CYP3A4 protein contents were also increased 3.0-fold by rifabutin treatment. Period: Sir Kenelm Digby, The Closet of Sir Kenelm Digby opened. 1669 ; John Gerard, The Herball or Generall Historie. 1597 ; William Harrison, The Description of England. 1577 ; Gervase Markham, The English Housewife. 1615 ; Sir Hugh Plat, The Jewel House of Art and Nature. 1594 ; Sir Hugh Plat, Delightes for Ladies. 1609 ; Thomas Tryon, A new Art of Brewing Beer, Ale and other sorts of Liquors. 1690 ; SCA: Master Corwin of Darkwater, SCUM vol 1-21 ; Newsletters of the Brewers Guilds of thelmearc and the East. Lady Arwen Evaine fert Rhys ap Gwynedd, The Compleat Anachronist 5, Handbook of Brewing. Cindy Renfrow, A Sip Through Time. Modern: Deni Bown, Encyclopedia of Herbs & their Uses. Charlie Papazian, The Home Brewer's Companion. Charlie Papazian, The New Complete Joy of Home Brewing and rimantadine. To study the infections in renal allograft recipients, their incidence, time of onset and influence of infections on allograft function.

11. Mercadante S, Casuccio A, Fulfaro F et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001; 19: 2898-904. Gagnon B, Bruera E. Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. J Pain Symptom Manage 1999; 18: 120-5. Mercadante S, Casuccio A, Calderone L. Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol 1999; 17: 3307-12. Hagen NA, Wasylenko E. Methadone: outpatient titration and monitoring strategies in cancer patients. J Pain Symptom Manage 1999; 18: 369-75. Krames E. The Bruera Neumann article reviewed. Discussion of Bruera E, Neumann CM. Role of methadone in the management of pain in cancer patients. Oncology 1999; 13: 1275-1282. Oncology 1999; 13: 1288-1289. Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain 1997; 70: 109-15. Garrido MJ, Troconiz IF. Methadone: a review of its pharmacokinetic pharmacodynamic properties. J Pharmacol Toxicol Methods 1999; 42: 61-6. Wolff K, Rostami-Hodjegan A, Shires S et al. The pharmacokinetics of methadone in healthy subjects and opiate users. Br J Clin Pharmacol 1997; 44: 325-34. Olsen GD, Wendel HA, Livermore JD, Leger RM, Lynn RK, Gerber N. Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. Clin Pharmacol Ther 1977; 21: 147-57. Verebely K, Volavka J, Mule S, Resnick R. Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther 1975; 18: 180-90. Inturrisi CE, Verebely K. Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther 1972; 13: 923-30. Wolff K, Rostami-Hodjegan A, Hay AW, Raistrick D, Tucker G. Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. Addiction 2000; 95: 1771-83. de Vos JW, Geerlings PJ, van den Brink W, Ufkes JG, van Wilgenburg H. Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. Eur J Clin Pharmacol 1995; 48: 361-6. Wolff K, Hay AW, Raistrick D, Calvert R. Steady-state pharmacokinetics of methadone in opioid addicts. Eur J Clin Pharmacol 1993; 44: 189-94. Nilsson MI, Gronbladh L, Widerlov E, Anggard E. Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures. Eur J Clin Pharmacol 1983; 25: 497-501. Anggard E, Nilsson MI, Holmstrand J, Gunne LM. Pharmacokinetics of methadone during maintenance therapy: pulse labeling with deuterated methadone in the steady state. Eur J Clin Pharmacol 1979; 16: 53-7. Nilsson MI, Anggard E, Holmstrand J, Gunne LM. Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase. Eur J Clin Pharmacol 1982; 22: 343-9. Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 1987; 41: 392-401. Gourlay GK, Cherry DA, Cousins MJ. A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 1986; 25: 297-312. Plummer JL, Gourlay GK, Cherry DA, Cousins MJ. Estimation of methadone clearance: application in the management of cancer pain. Pain 1988; 33: 313-22. Denson DD, Concilus RR, Warden G, Raj PP. Pharmacokinetics of continuous intravenous infusion of methadone in the early post-burn period. J Clin Pharmacol 1990; 30: 70-5. Grochow L, Sheidler V, Grossman S, Green L, Enterline J. Does intravenous methadone provide longer lasting analgesia than intravenous morphine? A randomized, double-blind study. Pain 1989; 38: 151-7. Hanson J, Ginman C, Hartvig P, et al. Clinical evaluation of oral methadone in treatment of cancer pain. Acta Anaesthesiol Scand 1982; 74: 124-127. Sawe J, Hansen J, Ginman C et al. Patient-controlled dose regimen of methadone for chronic cancer pain. Br Med J Clin Res Ed ; 1981; 282: 771-3. AHCPR. Management of Cancer Pain, Clinical Practice Guidelines. Rockville, MD: Agency for Health Care Policy and Research; U.S. Department of Health and Human Services; 1994. AHCPR Pub. No. 94-0592. 36. Health & Welfare Canada. Cancer pain: a monograph on the management of cancer pain. Ottawa, Canada: Health & Welfare Canada, Minister of Supply and Services; 1984. H42-2 5. 37. Twycross R, Lack S. Pain relief. In: Twycross R, Lack S, eds. Therapeutics in terminal cancer, 2nd edition. Edinburgh: Churchill Livingston; 1990; 2: 11-39. Levy MH. Pain management in advanced cancer. Semin Oncol 1985; 12: 394-410. Ripamonti C, De Conno F, Groff L et al. Equianalgesic dose ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Ann Oncol 1998; 9: 79-83. Bruera E, Neumann CM. Role of methadone in the management of pain in cancer patients. Oncology Huntingt ; 1999; 13: 1275-82; discussion 1285-8, 1291. 41. Davis MP, Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 2001; 9: 73-83. Jellin JM, Gregory P, Batz F, Hitchens K, et al. Pharmacist's Letter Prescriber's Letter Natural Medicines Comprehensive Database, 3rd ed. Stockton, CA: Therapeutic Research Faculty; 2000. 43. Brown LS, Sawyer RC, Li R, Cobb MN, Colborn DC, Narang PK. Lack of a pharmacologic interaction between rifabutin and methadone in HIV-infected former injecting drug users. Drug Alcohol Depend 1996; 43: 71-7. CPSO Task Force on CNMP. Evidence-based recommendations for medical management of chronic non-malignant pain: College of Physicians and Surgeons of Ontario CPSO Nov 2000. 45. De Conno F, Groff L, Brunelli C, Zecca E, Ventafridda V, Ripamonti C. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol 1996; 14: 2836-42. Friedman LL. Using Methadone. Lecture presented at: American Academy of Hospice and Palliative Medicine, 13th Annual Assembly; 22 June 2001; Phoenix, AZ. 47. Morley J, Makin M. The use of methadone in cancer pain poorly responsive to other opioids. Pain Rev 1998; 5: 51-58. Gardner-Nix JS. Oral methadone for managing chronic nonmalignant pain. J Pain Symptom Manage 1996; 11: 321-8. Novick DM, Kreek MJ, Fanizza AM, Yancovitz SR, Gelb AM, Stenger RJ. Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther 1981; 30: 353-62. Kreek MJ, Schecter AJ, Gutjahr CL, Hecht M. Methadone use in patients with chronic renal disease. Drug Alcohol Depend 1980; 5: 197-205. Portenoy RK. Pain specialists and addiction medicine specialists unite to address critical issues. American Pain Society Web site. APS bulletin online ; . 1999; 9 2 ; . Available at: : ampainsoc pub bulletin mar99 president . Accessed 5 October 2001 and rifabutin.

To distinguish dangerous from nondangerous patients. The likelihood ofaccunately predicting violent behavior among psychiatnic patients is low because the prevalence of battery, threatening behavior, and suicidal behavior among the general psychiatric population is low. Predicting violence among patients involuntarily committed because of violent behavior may yield higher posttest probabilities than found in this study of voluntarily admitted patients. Two studies have shown psychiatnists to be highly able to predict violent behaviors in involuntary psychiatric populations 12, 13 ; . Our study attempted to correct some of the methodological flaws in existing research by adopting a prospective design, assessing the reliability of the clinicians' predictions, operationalizing definitions of violent behavior, limiting the time frame of the prediction to seven days, and following the patients in a controlled setting. However, the study has several limitaiions, and its results should be extrapolated only to similar patient populations in which the prevalence of violent behavior is comparable. The small number of patients studied limited the power of the statistical analysis. Categonies that were found not to be statistically significant predictors of violent behavior may in fact have been found to be significant in a larger patient sample. To help in the prediction process, further research examining the prevalence of violent behavions in different populations is necessary. However, studies of effectiveness in predicting violent behavior in clinical settings are likely to remain problematic, since clinical assessment can predict only potential, not actual, behaviors. For example, when violent behavior is anticipated, appropriate clinical management steps are usually taken to avert the actual behavior. If the patient's actual behavior is the standard against which the prediction is compared, preventing the violent behavior may indicate a clinical success but would and rituxan.
Storey GD 2001 ; Alfred Baring Garrod 1819-1907 ; . Rheumatology Oxford ; 40: 1189-90. Straub RH, Muller-Ladner U, Lichtinger T, Scholmerich J, Menninger H and Lang B 1997 ; Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs. Br J Rheumatol 36: 1298-303.
Drug generally has been well tolerated at these doses, idiosyncratic liver toxicity has been noted in some patients 6 ; . Thiazoledinediones likely work in the context of type 2 diabetes through the activation of PPAR in adipose and or muscle cells, but the downstream target genes that are relevant to the insulin-sensitizing effects of these drugs are still unknown. PPAR is expressed at highest levels in adipose tissue 7, 8 ; . Its dominant role in the differentiation of this tissue was elucidated through experiments using exogenous expression and ligand activation in several fibroblastic cell lines. In this context, PPAR was shown to induce the morphology and the pattern of gene expression characteristic of terminally differentiated adipocytes 9 ; . More recently, it has been shown that PPAR is expressed at significant levels in nonadipose cells, including epithelial cells 1014 ; . Its physiological function in those tissues remains unknown, although activation seems to induce certain characteristics of differentiation appropriate for those cell types. Ligand activation of this receptor causes growth arrest in several cell types derived from tumors 1015 ; . Recently, we also have demonstrated that the administration of troglitazone to patients with liposarcoma dramatically enhances adipocytic differentiation, including increased expression of the genes of terminal cell differentiation and a reduction in expression of Ki-67, a histochemical marker for cell proliferation in vivo 16 ; . This is a striking example of induction of differentiation of solid tumors in humans. We recently have found naturally occurring somatic mutations in the gene encoding PPAR in a proportion of sporadic colorectal carcinomas 17 ; . Each of the mutations causes a profound loss of function on this receptor. One mutation causes a truncation before the ligand binding domain whereas the others result in mutant receptors that do not bind to either natural or synthetic ligands. These findings suggest that PPAR behaves like a tumor suppressor and that loss-of-function mutations might be etiologic for colorectal carcinogenesis. More importantly, our observations might suggest that examining for the presence of PPAR mutations before institution of ligand differentiation therapy might be useful to predict whether such therapy would result in a response and rms.

Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4 cell count. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 133: 493503. Currier, J. S., P. Williams, J. Feinberg, S. Becker, S. Owens, C. Fichtenbaum, and C. Benson. 2001. Impact of prophylaxis for Mycobacterium avium complex on bacterial infections in patients with advanced human immunodeficiency virus disease. Clin. Infect. Dis. 32: 16151622. Griffith, D. E., B. A. Brown, W. M. Girard, D. T. Murphy, and R. J. Wallace, Jr. 1996. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin. Infect. Dis. 23: 983989. Griffith, D. E., B. A. Brown, D. T. Murphy, W. M. Girard, L. Couch, and R. J. Wallace, Jr. 1998. Initial 6-month ; results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients. J. Infect. Dis. 178: 121 126. Griffith, D. E., B. A. Brown, P. Cegielski, D. T. Murphy, and R. J. Wallace, Jr. 2000. Early results at 6 months ; with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin. Infect. Dis. 30: 288292. Havlir, D. V., R. Haubrich, J. Hwang, M. W. Dunne, J. Currier, D. Forthal, F. Torriani, D. D. Richman, J. A. McCutchan, et al. 1998. Human immunodeficiency virus replication in AIDS patients with Mycobacterium avium complex bacteremia: a case control study. J. Infect. Dis. 177: 595599. Heifets, L., N. Mor, and J. Vanderkolk. 1993. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob. Agents Chemother. 37: 23642370. Heifets, L. 1996. Susceptibility testing of Mycobacterium avium complex isolates. Antimicrob. Agents Chemother. 40: 17591767. Heifets, L. B., P. J. Lindholm-Levy, and R. D. Comstock. 1992. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. Am. Rev. Respir. Dis. 145: 856858. Horsburgh, C. R., Jr. 1991. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N. Engl. J. Med. 324: 13321338. Inderlied, C. B., C. A. Kemper, and L. E. M. Bermudez. 1993. The Mycobacterium avium complex. Clin. Microbiol. Rev. 6: 266310. Inderlied, C. B. 1997. Microbiology and minimum inhibitory concentration testing for Mycobacterium avium complex prophylaxis. Am. J. Med. 102: 210. Koletar, S. L., A. J. Berry, M. H. Cynamon, J. Jacobson, J. S. Currier, R. R. MacGregor, M. W. Dunne, and D. J. Williams. 1999. Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients. Antimicrob. Agents Chemother. 43: 28692872. Meier, A., L. Heifets, R. J. Wallace, Jr., Y. Zhang, B. A. Brown, P. Sander, and E. C. Bottger. 1996. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J. Infect. Dis. 174: 354360. NCCLS. Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes. Approved standard M24-A, in press. NCCLS, Wayne, Pa. Prince, D. S., D. D. Peterson, R. M. Steiner, J. E. Gottlieb, R. Scott, H. L. Israel, W. G. Figueroa, and J. E. Fish. 1989. Infection with Mycobacterium avium complex in patients without predisposing conditions. N. Engl. J. Med. 321: 863868. Shafran, S. D., J. A. Talbot, S. Chomyc, E. Davison, J. Singer, P. Phillips, I. Salit, S. L. Walmsley, I. W. Fong, M. J. Gill, A. R. Rachlis, and R. G. Lalonde. 1998. Does in vitro susceptibility to rifabutin and ethambutol predict the response to treatment of Mycobacterium avium complex bacteremia with rifabutin, ethambutol, and clarithromycin? Clin. Infect. Dis. 27: 1401 1405. Siddiqi, S. H., L. B. Heifets, M. H. Cynamon, N. M. Hooper, A. Laszlo, J. P. Libonati, P. J. Lindholm-Levy, and N. Pearson. 1993. Rapid broth macrodilution method for determination of MICs for Mycobacterium avium isolates. J. Clin. Microbiol. 31: 23322338. Wallace, R. J., Jr., B. A. Brown, D. E. Griffith, W. M. Girard, and D. T. Murphy. 1996. Clarithromycin regimens for pulmonary Mycobacterium avium complex--the first 50 patients. Am. J. Respir. Crit. Care Med. 153: 17661772. Wallace, R. J., Jr., J. L. Cook, J. Glassroth, D. E. Griffith, K. N. Olivier, and F. Gordon. 1997. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. American Thoracic Society Statement. Am. J. Respir. Crit. Care Med. 156: S1S25. Wallace, R. J., Jr., Y. Zhang, B. A. Brown, D. Dawson, D. T. Murphy, R. Wilson, and D. E. Griffith. 1998. Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. Am. J. Respir. Crit. Care Med. 158: 12351244 and rifadin. Interacting Drug Azathioprine Carbamazepine Colestyramine Oral contraceptives Phenobarbitone Phenytoin Rifabutin Comments Monitor as warfarin dose may need to be increased Dose of warfarin may need to be increased monitor closely. Alternatively no interaction with oxcarbazepine Enhance or reduce effect of warfarin monitor closely and adjust warfarin dose accordingly Generally avoid in thromboembolic disorders May require 30 60% increase in warfarin dose. Persists for up to 6 weeks on stopping phenobarbitone. Monitor May reduce or enhance anticoagulant effects monitor Monitor closely. Reduces anticoagulant effects within 5 7 days. Warfarin dose may need to be doubled or trebled and reduced on stopping Rifampicin Rifabutin Monitor closely. Reduces anticoagulant effects within 5 7 days. Warfarin dose may need to be doubled or trebled and reduced on stopping Rifampicin Rifabutin If patients are warfarin resistant it may be worth considering this interaction. Vitamin K may be present in enteral feeds, health foods, food supplements, green tea and robaxin.